-
Unique Focus and Experience
Daniel is a member of the firm’s global generic pharmaceutical industry group and also has over 20 years of experience focused on corporate and securities matters, including M&A, public offerings and financings, and related corporate governance matters.
Daniel Keating is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where his practice primarily focuses on corporate and securities matters, including sophisticated domestic and international transactions. He is also a member of the firm’s global generic pharmaceutical industry group.
Dan has more than 20 years of legal experience. He has represented clients in mergers and acquisitions, public offerings, and financings, as well as related corporate governance matters. In particular, Dan has substantial experience representing multinational companies on cross-border M&A deals and complex commercial transactions. Dan’s clients include companies across a diverse range of industries, including technology, fintech, financial, pharmaceutical, and life sciences.
Prior to joining the firm, Dan was a was a corporate partner in an international law firm based in that firm’s Washington, D.C., office. In this role, he advised on a variety of corporate matters, including representing a pharmaceutical company in the acquisition of numerous product portfolios in dozens of countries worldwide. He also acted as underwriters' counsel for numerous offerings of debt and equity securities.
Daniel Keating is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where his practice primarily focuses on corporate and securities matters, including sophisticated domestic and international transactions. He is also a member of the firm’s global generic pharmaceutical industry group.
Dan has more than 20 years of legal experience. He has represented clients in mergers and acquisitions, public offerings, and financings, as well as related corporate governance matters. In particular, Dan has substantial experience representing multinational companies on cross-border M&A deals and complex commercial transactions. Dan’s clients include companies across a diverse range of industries, including technology, fintech, financial, pharmaceutical, and life sciences.
Prior to joining the firm, Dan was a was a corporate partner in an international law firm based in that firm’s Washington, D.C., office. In this role, he advised on a variety of corporate matters, including representing a pharmaceutical company in the acquisition of numerous product portfolios in dozens of countries worldwide. He also acted as underwriters' counsel for numerous offerings of debt and equity securities.
- J.D., Georgetown University Law Center, 1996
- B.S., Michigan State University, 1992Summa Cum Laude
- Selected for inclusion in the “Finance: Capital Markets: Equity Offerings” category in the 2017 edition of The Legal 500 US
- Selected for inclusion in the “Finance: Financial Services: Regulatory” category in the 2012 and 2014 editions of The Legal 500 US
- Recognized in the “Nationwide—Financial Services Regulation: Financial Institutions M&A” category in the 2010-2012 editions of Chambers USA: America's Leading Lawyers for Business
- Named in the “Mergers, Acquisitions, and Buyouts” category in the 2012 edition of The Legal 500 US
- Bar of the District of Columbia
- State Bar of New York
- J.D., Georgetown University Law Center, 1996
- B.S., Michigan State University, 1992Summa Cum Laude
- Selected for inclusion in the “Finance: Capital Markets: Equity Offerings” category in the 2017 edition of The Legal 500 US
- Selected for inclusion in the “Finance: Financial Services: Regulatory” category in the 2012 and 2014 editions of The Legal 500 US
- Recognized in the “Nationwide—Financial Services Regulation: Financial Institutions M&A” category in the 2010-2012 editions of Chambers USA: America's Leading Lawyers for Business
- Named in the “Mergers, Acquisitions, and Buyouts” category in the 2012 edition of The Legal 500 US
- Bar of the District of Columbia
- State Bar of New York
Select Publications
- Co-author, “New SEC Guidance and PCAOB Auditing Standard No. 5 Provide Clarity on SOX Section 404,” Bloomberg Law Reports—Securities Law, September 17, 2007
- “End of an Era,” Legal Week Global, August 26, 2004
Select Publications
- Co-author, “New SEC Guidance and PCAOB Auditing Standard No. 5 Provide Clarity on SOX Section 404,” Bloomberg Law Reports—Securities Law, September 17, 2007
- “End of an Era,” Legal Week Global, August 26, 2004
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes: